Atom Investors LP Has $7.49 Million Position in Dianthus Therapeutics, Inc. $DNTH

Atom Investors LP raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 197.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 181,860 shares of the company’s stock after purchasing an additional 120,822 shares during the period. Atom Investors LP owned 0.42% of Dianthus Therapeutics worth $7,494,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics in the second quarter valued at $27,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Dianthus Therapeutics in the fourth quarter valued at $40,000. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics in the third quarter valued at $64,000. Tower Research Capital LLC TRC increased its holdings in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after purchasing an additional 542 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on DNTH shares. Stifel Nicolaus set a $120.00 price objective on shares of Dianthus Therapeutics in a report on Monday, March 9th. Wells Fargo & Company initiated coverage on shares of Dianthus Therapeutics in a report on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price objective on the stock. Wedbush upped their price target on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Dianthus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $117.82.

Dianthus Therapeutics Stock Down 4.4%

DNTH opened at $78.88 on Wednesday. Dianthus Therapeutics, Inc. has a twelve month low of $16.64 and a twelve month high of $96.50. The company has a 50-day simple moving average of $86.88 and a 200 day simple moving average of $65.73. The stock has a market capitalization of $4.31 billion, a price-to-earnings ratio of -19.10 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The business had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Insider Activity

In related news, EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at $362,480. This represents a 86.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Ryan Savitz sold 8,224 shares of the company’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $89.84, for a total transaction of $738,844.16. Following the sale, the executive vice president directly owned 8,224 shares of the company’s stock, valued at $738,844.16. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 149,121 shares of company stock valued at $12,635,454 in the last ninety days. 3.02% of the stock is currently owned by company insiders.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.